Nothing Special   »   [go: up one dir, main page]

AU2001258536A1 - Derivatisation of proteins in aqueous solution - Google Patents

Derivatisation of proteins in aqueous solution

Info

Publication number
AU2001258536A1
AU2001258536A1 AU2001258536A AU5853601A AU2001258536A1 AU 2001258536 A1 AU2001258536 A1 AU 2001258536A1 AU 2001258536 A AU2001258536 A AU 2001258536A AU 5853601 A AU5853601 A AU 5853601A AU 2001258536 A1 AU2001258536 A1 AU 2001258536A1
Authority
AU
Australia
Prior art keywords
derivatization
groups
denaturant
vivo
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001258536A
Inventor
Gregory Gregoriadis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lipoxen Technologies Ltd
Original Assignee
Lipoxen Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipoxen Technologies Ltd filed Critical Lipoxen Technologies Ltd
Publication of AU2001258536A1 publication Critical patent/AU2001258536A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01006—Catalase (1.11.1.6)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

Abstract

Proteins are derivitized by reaction of pendant groups, usually groups which are side chains in non-terminal amino acyl units of the protein, in aqueous reactions in the presence of a denaturant. The denaturant is preferably an amphiphilic compound, most preferably an anionic amphiphilic compound such as a long chain alkyl sulphate mono ester, preferably an alkaline metal salt, for instance sodium dodecyl sulphate. The degree of derivatization is increased, while the protein retains activity, such as enzyme activity. The increase in the degree of derivatization enhances the increase in circulation time in vivo and stability on storage and in vivo. Preferably the derivatizing reagent is an aldehyde compound which reacts with primary amine groups, generally the epsilon-amino group of lysyl units. Derivatization is conducted under reducing conditions to generate a secondary amine derivative.
AU2001258536A 2000-05-16 2001-05-14 Derivatisation of proteins in aqueous solution Abandoned AU2001258536A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00304108.4 2000-05-16
EP00304108 2000-05-16
PCT/GB2001/002115 WO2001087922A2 (en) 2000-05-16 2001-05-14 Derivatisation of proteins in aqueous solution

Publications (1)

Publication Number Publication Date
AU2001258536A1 true AU2001258536A1 (en) 2001-11-26

Family

ID=8172993

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001258536A Abandoned AU2001258536A1 (en) 2000-05-16 2001-05-14 Derivatisation of proteins in aqueous solution

Country Status (8)

Country Link
US (1) US6962972B2 (en)
EP (1) EP1335931B1 (en)
JP (1) JP2003533537A (en)
AT (1) ATE313554T1 (en)
AU (1) AU2001258536A1 (en)
DE (1) DE60116137T2 (en)
ES (1) ES2256234T3 (en)
WO (1) WO2001087922A2 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1654290B1 (en) 2003-08-12 2019-03-13 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
JP2007501888A (en) * 2003-08-12 2007-02-01 リポクセン テクノロジーズ リミテッド Polysialic acid derivatives
CN101039964B (en) 2004-08-12 2012-11-14 利普生技术有限公司 Fractionation of charged polysaccharide
US7875708B2 (en) 2004-08-12 2011-01-25 Lipoxen Technologies Limited Sialic acid derivatives
TWI376234B (en) 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
WO2006090119A1 (en) 2005-02-23 2006-08-31 Lipoxen Technologies Limited Activated sialic acid derivatives for protein derivatisation and conjugation
EP2043692B1 (en) * 2006-07-25 2016-05-18 Lipoxen Technologies Limited Polysaccharide derivatives of erythropoietin
PL2115010T3 (en) 2007-02-28 2012-07-31 Lipoxen Tech Limited Reduction of endotoxin in polysialic acids
AU2010277438B2 (en) 2009-07-27 2015-08-20 Baxalta GmbH Glycopolysialylation of non-blood coagulation proteins
NZ623810A (en) * 2009-07-27 2015-10-30 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
EP2470559B1 (en) 2009-08-24 2017-03-22 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
EA201691292A1 (en) 2010-07-30 2017-08-31 Баксалта Инкорпорейтид NUCLEOPHILIC CATALYSTS FOR OXYM BINDING
EP2714093A1 (en) 2011-05-27 2014-04-09 Baxter International Inc. Therapeutic proteins with increased half-life and methods of preparing same
PT2717898T (en) 2011-06-10 2019-05-20 Bioverativ Therapeutics Inc Pro-coagulant compounds and methods of use thereof
MX357403B (en) 2012-01-12 2018-07-09 Bioverativ Therapeutics Inc Chimeric factor viii polypeptides and uses thereof.
MY188897A (en) 2012-02-15 2022-01-12 Bioverativ Therapeutics Inc Factor viii compositions and methods of making and using same
WO2013123457A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
AU2013204754C1 (en) 2012-05-16 2018-10-11 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage
EP2863940A4 (en) 2012-06-08 2016-08-10 Biogen Ma Inc Chimeric clotting factors
EP2858659B1 (en) 2012-06-08 2019-12-25 Bioverativ Therapeutics Inc. Procoagulant compounds
PL2882450T3 (en) 2012-07-11 2020-06-29 Bioverativ Therapeutics Inc. Factor viii complex with xten and von willebrand factor protein, and uses thereof
KR102666819B1 (en) 2013-06-28 2024-05-23 바이오버라티브 테라퓨틱스 인크. Thrombin cleavable linker with xten and its uses thereof
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
HUE057005T2 (en) 2013-09-25 2022-04-28 Bioverativ Therapeutics Inc On-column viral inactivation methods
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
JP6749836B2 (en) 2014-01-10 2020-09-02 バイオベラティブ セラピューティクス インコーポレイテッド Factor VIII chimeric protein and uses thereof
US10188739B2 (en) 2014-02-27 2019-01-29 Xenetic Biosciences, Inc. Compositions and methods for administering insulin or insulin-like protein to the brain
CA2962486A1 (en) 2014-09-26 2016-03-31 Bayer Pharma Aktiengesellschaft Stabilized adrenomedullin derivatives and use thereof
DK3207130T3 (en) 2014-10-14 2019-11-11 Halozyme Inc Compositions of Adenosine Deaminase-2 (ADA2), Variants thereof, and Methods for Using the Same
MA40835A (en) 2014-10-23 2017-08-29 Biogen Ma Inc ANTI-GPIIB / IIIA ANTIBODIES AND THEIR USES
MA40861A (en) 2014-10-31 2017-09-05 Biogen Ma Inc ANTI-GLYCOPROTEIN IIB / IIIA ANTIBODIES
UA126016C2 (en) 2015-08-03 2022-08-03 Біовератів Терапеутікс Інк. Factor ix fusion proteins and methods of making and using same
CA3007364A1 (en) 2015-12-03 2017-06-08 Baxalta Incorporated Factor viii with extended half-life and reduced ligand-binding properties
MA45473A (en) 2016-04-04 2019-02-13 Shire Human Genetic Therapies CONJUGATE C1 ESTERASE INHIBITOR AND ITS USES
PE20210313A1 (en) 2018-03-28 2021-02-12 Bristol Myers Squibb Co INTERLEUKIN-2 FUSION PROTEINS / INTERLEUKIN-2 ALPHA RECEPTOR AND METHODS OF USE
CN112512555A (en) 2018-05-18 2021-03-16 比奥维拉迪维治疗股份有限公司 Methods of treating hemophilia A
CA3104686A1 (en) 2018-07-03 2020-01-09 Bristol-Myers Squibb Company Fgf-21 formulations
CN114174326A (en) 2019-06-18 2022-03-11 拜耳公司 Long-term stable adrenomedullin analogues and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
GB9112212D0 (en) 1991-06-06 1991-07-24 Gregoriadis Gregory Pharmaceutical compositions
US5846951A (en) * 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process

Also Published As

Publication number Publication date
DE60116137D1 (en) 2006-01-26
ATE313554T1 (en) 2006-01-15
WO2001087922A2 (en) 2001-11-22
EP1335931B1 (en) 2005-12-21
DE60116137T2 (en) 2006-08-24
EP1335931A2 (en) 2003-08-20
US20030129159A1 (en) 2003-07-10
US6962972B2 (en) 2005-11-08
JP2003533537A (en) 2003-11-11
ES2256234T3 (en) 2006-07-16
WO2001087922A3 (en) 2003-05-30

Similar Documents

Publication Publication Date Title
AU2001258536A1 (en) Derivatisation of proteins in aqueous solution
Jahngen-Hodge et al. Regulation of ubiquitin-conjugating enzymes by glutathione following oxidative stress
Pinkus [45] Glutamine binding sites
MA23825A1 (en) SYNTHESIS OF BLEACHING ACTIVATORS
EA199900980A1 (en) IMPROVED WAYS TO PREPARE ACTIVATED PROTEIN C
DE69621953D1 (en) VEHICLE FOR INSERTING NUCLEIC ACIDS IN CELLS
BR9612006A (en) Process for making an aqueous solution containing at least 30 percent by weight of (meth) acrylic acid or salt thereof and below 0.2% of (meth) acrylonitrile
ES2152813B1 (en) OPEN CELL POLYURETHANE CELLULAR PRODUCTS.
ES2136418T3 (en) DETERMINATION OF GLYCOSILATED PROTEINS.
ES2076398T3 (en) PROCEDURE FOR THE PREPARATION OF L-ORNITHINE SALTS.
BR0002854A (en) Animal food supplements containing aqueous lysine and process for their production
Dannenberg Jr et al. Histochemical demonstration of hydrogen peroxide production by leukocytes in fixed‐frozen tissue sections of inflammatory lesions
BR0115418A (en) Process
ATE227705T1 (en) GUANIDINYLATION REAGENT
BR9712575A (en) Process for restoring cells that have a mutated p53 protein, a p53-dependent transactivation activity, uses a single chain antibody capable of specifically binding a mutated p53 protein, and a coding nucleic acid, molecule 11d3 or a variant, nucleic acid and composition
Elliott et al. Relationship between a tumor promoter-induced decrease in queuine modification of transfer RNA in normal human cells and the expression of an altered cell phenotype
HIGASHI et al. Re-evaluation of protein-bound glutathione in rat liver
NO20003880L (en) Transfectants which are sensitive to reducing conditions, pharmaceutical preparations containing them and their uses
Kulmacz Concerted loss of cyclooxygenase and peroxidase activities from prostaglandin H synthase upon proteolytic attack
Fujioka et al. Function and reactivity of sulfhydryl groups of rat liver glycine methyltransferase
Juknat et al. Studies on uroporphyrinogen decarboxylase of etiolate Euglena gracilis Z.
PT979036E (en) ENZYMATIC CONCENTRATE
KUBOTA et al. Carboxypeptidases from the exocarp of mandarin orange (Citrus unshiu MARC.). II. Chemical and enzymatic properties of carboxypeptidases Cua and Cub
Strom et al. Enoyl coenzyme A reduction by bovine mammary fatty acid synthetase. Specificity and other characteristics.
García-Carreño et al. Control of digestive functions in shrimp, I. An inhibitor of trypsin activity in the hepatopancreas